SGHT
Sight Sciences, Inc. NASDAQ Listed Jul 15, 2021$5.29
Mkt Cap $285.7M
52w Low $2.81
38.6% of range
52w High $9.24
50d MA $4.07
200d MA $5.13
P/E (TTM)
-6.0x
EV/EBITDA
-9.9x
P/B
3.6x
Debt/Equity
0.6x
ROE
-60.1%
P/FCF
-13.8x
RSI (14)
—
ATR (14)
—
Beta
2.49
50d MA
$4.07
200d MA
$5.13
Avg Volume
339.3K
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
4040 Campbell Avenue · Menlo Park, CA 94025 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.19 | -0.24 | -26.3% | 4.30 | +1.4% | +23.0% | — | — | — | — | — |
| Mar 4, 2026 | AMC | -0.15 | -0.08 | +46.7% | 5.41 | -11.3% | -26.8% | -6.3% | +10.2% | -2.0% | -7.7% | — |
| Nov 6, 2025 | AMC | -0.26 | -0.16 | +38.5% | 5.00 | +9.8% | +16.4% | +12.0% | +8.0% | +9.7% | -8.7% | — |
| Aug 7, 2025 | AMC | -0.25 | -0.23 | +8.0% | 3.55 | +7.6% | +19.4% | -2.8% | +3.2% | +0.0% | +0.0% | — |
| May 8, 2025 | AMC | -0.29 | -0.28 | +3.4% | 3.03 | +11.6% | +1.7% | +4.2% | +6.5% | -4.1% | +4.3% | — |
| Mar 5, 2025 | AMC | -0.22 | -0.23 | -4.5% | 2.42 | -7.0% | +2.9% | -5.2% | +3.8% | +13.9% | -3.6% | — |
| Nov 7, 2024 | AMC | -0.23 | -0.22 | +4.3% | 4.68 | -4.9% | -9.6% | +8.5% | -7.8% | -5.9% | -3.0% | — |
| Aug 1, 2024 | AMC | -0.31 | -0.25 | +19.4% | 7.42 | -4.0% | -15.0% | -12.5% | -0.5% | +0.4% | +5.8% | — |
| May 2, 2024 | AMC | -0.29 | -0.33 | -13.8% | 5.61 | +0.0% | +6.2% | -2.3% | -2.9% | -1.8% | +0.2% | — |
| Mar 7, 2024 | AMC | -0.35 | -0.22 | +37.1% | 4.60 | +5.0% | +6.1% | -8.4% | -2.2% | +0.0% | +0.9% | — |
| Nov 7, 2023 | AMC | -0.31 | -0.27 | +12.9% | 2.10 | -16.7% | -1.9% | -14.8% | +0.0% | +2.8% | +14.1% | — |
| Aug 3, 2023 | AMC | -0.35 | -0.30 | +14.3% | 8.04 | +0.6% | +7.6% | -6.0% | -0.2% | -2.6% | -0.8% | — |
| May 4, 2023 | AMC | -0.41 | -0.35 | +14.6% | 10.67 | +2.8% | -6.3% | +5.2% | -4.0% | -1.0% | -0.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | UBS | Maintains | Buy → Buy | — | $3.96 | $3.80 | -4.0% | -6.3% | +10.2% | -2.0% | -7.7% | -2.2% |
| Mar 6 | Citigroup | Maintains | Neutral → Neutral | — | $3.96 | $3.80 | -4.0% | -6.3% | +10.2% | -2.0% | -7.7% | -2.2% |
| Mar 2 | Stifel | Maintains | Buy → Buy | — | $5.16 | $5.19 | +0.6% | +8.9% | -6.4% | +2.9% | -26.8% | -6.3% |
| Jan 5 | Piper Sandler | Upgrade | Neutral → Overweight | — | $7.48 | $7.95 | +6.3% | +3.1% | -3.1% | -0.4% | +1.2% | -4.6% |
| Dec 23 | UBS | Maintains | Buy → Buy | — | $8.44 | $8.74 | +3.6% | +0.0% | +7.2% | -2.5% | -2.0% | -7.4% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $8.46 | $8.56 | +1.2% | -2.1% | -2.2% | +2.6% | +1.0% | -2.9% |
| Dec 10 | Lake Street | Maintains | Buy → Buy | — | $8.34 | $8.44 | +1.2% | +1.4% | -2.1% | -2.2% | +2.6% | +1.0% |
| Dec 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.17 | $8.29 | +1.5% | +1.6% | +3.1% | -2.6% | -3.5% | +6.0% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $5.82 | $5.85 | +0.5% | +12.0% | +8.0% | +9.7% | -8.7% | +0.9% |
| Nov 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.00 | $5.49 | +9.8% | +16.4% | +12.0% | +8.0% | +9.7% | -8.7% |
| Oct 21 | Lake Street | Maintains | Buy → Buy | — | $4.66 | $4.65 | -0.2% | +10.7% | -0.6% | +1.6% | +1.3% | -2.1% |
| Oct 7 | Citigroup | Maintains | Neutral → Neutral | — | $3.36 | $3.35 | -0.3% | +3.3% | +0.0% | -2.6% | -5.3% | +1.9% |
| Aug 28 | Needham | Maintains | Hold → Hold | — | $4.23 | $4.23 | +0.0% | -4.5% | +0.5% | -4.7% | -1.8% | -1.8% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $4.07 | $4.07 | +0.0% | +1.2% | +2.7% | -0.5% | +0.5% | +0.0% |
| Aug 8 | Lake Street | Upgrade | Hold → Buy | — | $3.55 | $3.82 | +7.6% | +19.4% | -2.8% | +3.2% | +0.0% | +0.0% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.70 | $3.73 | +0.8% | -9.7% | +5.1% | +0.9% | -1.1% | -2.0% |
| Jun 18 | Piper Sandler | Maintains | Neutral → Neutral | — | $4.03 | $4.02 | -0.2% | +6.0% | -4.9% | +6.9% | -1.8% | -0.9% |
| May 22 | Citigroup | Maintains | Neutral → Neutral | — | $3.24 | $3.24 | +0.0% | +1.2% | -2.4% | +7.5% | +4.9% | -2.5% |
| May 9 | Lake Street | Maintains | Hold → Hold | — | $3.03 | $3.38 | +11.6% | +1.7% | +4.2% | +6.5% | -4.1% | +4.3% |
| Apr 9 | Needham | Maintains | Hold → Hold | — | $2.09 | $2.05 | -1.9% | +12.4% | -3.8% | +5.3% | +1.3% | +4.6% |
| Mar 6 | Lake Street | Maintains | Hold → Hold | — | $2.42 | $2.25 | -7.0% | +2.9% | -5.2% | +3.8% | +13.9% | -3.6% |
| Mar 6 | Needham | Maintains | Hold → Hold | — | $2.42 | $2.25 | -7.0% | +2.9% | -5.2% | +3.8% | +13.9% | -3.6% |
| Mar 6 | Stifel | Maintains | Buy → Buy | — | $2.42 | $2.25 | -7.0% | +2.9% | -5.2% | +3.8% | +13.9% | -3.6% |
| Mar 6 | Piper Sandler | Maintains | Neutral → Neutral | — | $2.42 | $2.25 | -7.0% | +2.9% | -5.2% | +3.8% | +13.9% | -3.6% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $2.51 | $2.43 | -3.2% | -1.6% | -2.0% | +2.9% | -5.2% | +3.8% |
| Feb 6 | Stifel | Maintains | Buy → Buy | — | $2.87 | $2.85 | -0.7% | -5.6% | +2.2% | -3.6% | -0.4% | -3.8% |
| Jan 27 | UBS | Maintains | Buy → Buy | — | $2.93 | $2.89 | -1.4% | -0.3% | +7.2% | -2.6% | -2.6% | -5.7% |
| Jan 15 | Lake Street | Maintains | Hold → Hold | — | $3.15 | $3.16 | +0.3% | -1.3% | -8.7% | -0.4% | +2.1% | -0.3% |
| Jan 14 | Needham | Maintains | Hold → Hold | — | $3.24 | $3.24 | +0.0% | -2.8% | -1.3% | -8.7% | -0.4% | +2.1% |
| Dec 11 | Citigroup | Maintains | Neutral → Neutral | — | $3.91 | $3.95 | +1.0% | -0.3% | -4.6% | -3.8% | +2.0% | -0.8% |
| Nov 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.23 | $4.16 | -1.7% | +8.5% | -7.8% | -5.9% | -3.0% | -1.6% |
| Nov 8 | Piper Sandler | Maintains | Neutral → Neutral | — | $4.68 | $4.45 | -4.9% | -9.6% | +8.5% | -7.8% | -5.9% | -3.0% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.61 | $7.64 | +0.4% | +2.8% | +6.3% | -1.8% | -6.1% | -0.7% |
| Jul 10 | Citigroup | Maintains | Neutral → Neutral | — | $6.43 | $6.45 | +0.3% | -4.4% | +22.3% | +1.2% | +2.8% | +6.3% |
| May 3 | Piper Sandler | Maintains | Neutral → Neutral | — | $5.61 | $5.61 | +0.0% | +6.2% | -2.3% | -2.9% | -1.8% | +0.2% |
| Mar 8 | Stifel | Maintains | Buy → Buy | — | $4.60 | $4.83 | +5.0% | +6.1% | -8.4% | -2.2% | +0.0% | +0.9% |
| Dec 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.90 | $3.05 | +5.2% | +0.7% | -2.1% | -2.1% | -5.4% | +8.3% |
| Nov 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $2.10 | $1.75 | -16.7% | -1.9% | -14.8% | +0.0% | +2.8% | +14.1% |
| Sep 18 | Stifel | Maintains | Buy → Buy | — | $3.45 | $3.40 | -1.4% | -2.0% | -8.3% | -7.1% | +2.8% | +3.0% |
| Sep 15 | Citigroup | Maintains | Neutral → Neutral | — | $3.49 | $3.48 | -0.3% | -1.1% | -2.0% | -8.3% | -7.1% | +2.8% |
| Sep 13 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $3.28 | $3.23 | -1.5% | +0.6% | +5.8% | -1.1% | -2.0% | -8.3% |
| Sep 13 | BofA Securities | Downgrade | Neutral → Underperform | — | $3.28 | $3.23 | -1.5% | +0.6% | +5.8% | -1.1% | -2.0% | -8.3% |
| Sep 12 | Piper Sandler | Downgrade | Overweight → Neutral | — | $6.51 | $3.81 | -41.5% | -49.6% | +0.6% | +5.8% | -1.1% | -2.0% |
| Sep 12 | William Blair | Downgrade | Outperform → Market Perform | — | $6.51 | $3.81 | -41.5% | -49.6% | +0.6% | +5.8% | -1.1% | -2.0% |
| Sep 12 | BofA Securities | Downgrade | Neutral → Underperform | — | $6.51 | $3.81 | -41.5% | -49.6% | +0.6% | +5.8% | -1.1% | -2.0% |
| Aug 24 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $6.94 | $6.52 | -6.1% | -9.3% | +1.4% | -0.8% | +8.1% | -4.2% |
| Aug 21 | Citigroup | Maintains | Neutral → Neutral | — | $7.30 | $7.17 | -1.8% | -1.8% | -1.8% | -1.4% | -9.3% | +1.4% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $8.04 | $8.09 | +0.6% | +7.6% | -6.0% | -0.2% | -2.6% | -0.8% |
| Jul 11 | Citigroup | Downgrade | Buy → Neutral | — | $8.05 | $8.04 | -0.1% | -6.6% | +0.8% | +2.9% | -0.1% | -6.0% |
| Jul 10 | Citigroup | Downgrade | Buy → Neutral | — | $8.55 | $8.04 | -6.0% | -5.8% | -6.6% | +0.8% | +2.9% | -0.1% |
No insider trades available.
8-K · 2.02
!! High
Sight Sciences, Inc. -- 8-K 2.02: Earnings Results
Sight Sciences (SGHT) released Q1 2026 earnings results on May 6, showing operational performance metrics that investors should review in the attached press release for revenue, profitability, and guidance implications.
May 6
8-K · 7.01
! Medium
Sight Sciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sight Sciences lost its patent infringement case against Alcon regarding the Hydrus Microstent, eliminating a potential competitive advantage and removing litigation-related upside for the company.
Apr 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
SGHT's core patents face USPTO validity challenges that could weaken its litigation position and competitive moat if claims are ultimately invalidated, despite available appeal options.
Mar 30
8-K · 7.01
! Medium
Sight Sciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Sight Sciences disclosed an investor presentation that may be used in upcoming communications with investors and analysts to discuss the company's business and strategy.
Mar 4
8-K · 1.01
!! High
Sight Sciences, Inc. -- 8-K 1.01: Material Agreement
Sight Sciences signed an agreement with Deerfield Campbell, LLC, potentially indicating a strategic partnership or financing arrangement that could impact the company's operational or financial position.
Feb 3
Data updated apr 27, 2026 12:58am
· Source: massive.com